The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib

BACKGROUND: The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy can be measured based on the rate of treatment response, based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or progression-free survival (PFS). However, there are some p...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Tuberc Respir Dis (Seoul)
Asıl Yazarlar: Park, Dong Il, Kim, Sun Young, Kim, Ju Ock, Jung, Sung Soo, Park, Hee Sun, Moon, Jae Young, Chung, Chae Uk, Kim, Song Soo, Seo, Jae Hee, Lee, Jeong Eun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The Korean Academy of Tuberculosis and Respiratory Diseases 2015
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4620323/
https://ncbi.nlm.nih.gov/pubmed/26508917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4046/trd.2015.78.4.315
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller